𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

✍ Scribed by Seymour, Matthew T; Brown, Sarah R; Middleton, Gary; Maughan, Timothy; Richman, Susan; Gwyther, Stephen; Lowe, Catherine; Seligmann, Jennifer F; Wadsley, Jonathan; Maisey, Nick; Chau, Ian; Hill, Mark; Dawson, Lesley; Falk, Stephen; O'Callaghan, Ann; Benstead, Kim; Chambers, Philip; Oliver, Alfred; Marshall, Helen; Napp, Vicky; Quirke, Phil

Book ID
120422624
Publisher
The Lancet
Year
2013
Tongue
English
Weight
420 KB
Volume
14
Category
Article
ISSN
1470-2045

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Randomised trial of irinotecan plus supp
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
✍ David Cunningham; Seppo PyrhΓΆnen; Roger D James; Cornelis JA Punt; Tamas F Hicki πŸ“‚ Article πŸ“… 1998 πŸ› The Lancet 🌐 English βš– 169 KB

Background In phase II studies, irinotecan is active in metastatic colorectal cancer, but the overall benefit has not been assessed in a randomised clinical trial. Methods Patients with proven metastatic colorectal cancer, which had progressed within 6 months of treatment with fluorouracil, were ra